Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1172/jci.insight.148855 http://scihub22266oqcxt.onion/10.1172/jci.insight.148855 34081630!8410046!34081630     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       JCI+Insight 2021 ; 6 (13): ä Nephropedia Template TP {{tp|p=34081630|t=2021. Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern |pdf=|usr=}}{{34081630}} gab.com Text Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern JO: JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=34081630 #FOAvip BACKGROUNDThe role of humoral immunity in COVID-19 is not fully understood, owing, in large part, to the complexity of antibodies produced in response to the SARS-CoV-2 infection. There is a pressing need for serology tests to assess patient-specific antibody response and predict clinical outcome.METHODSUsing SARS-CoV-2 proteome and peptide microarrays, we screened 146 COVID-19 patients' plasma samples to identify antigens and epitopes. This enabled us to develop a master epitope array and an epitope-specific agglutination assay to gauge antibody responses systematically and with high resolution.RESULTSWe identified linear epitopes from the spike (S) and nucleocapsid (N) proteins and showed that the epitopes enabled higher resolution antibody profiling than the S or N protein antigen. Specifically, we found that antibody responses to the S-811-825, S-881-895, and N-156-170 epitopes negatively or positively correlated with clinical severity or patient survival. Moreover, we found that the P681H and S235F mutations associated with the coronavirus variant of concern B.1.1.7 altered the specificity of the corresponding epitopes.CONCLUSIONEpitope-resolved antibody testing not only affords a high-resolution alternative to conventional immunoassays to delineate the complex humoral immunity to SARS-CoV-2 and differentiate between neutralizing and non-neutralizing antibodies, but it also may potentially be used to predict clinical outcome. The epitope peptides can be readily modified to detect antibodies against variants of concern in both the peptide array and latex agglutination formats.FUNDINGOntario Research Fund (ORF) COVID-19 Rapid Research Fund, Toronto COVID-19 Action Fund, Western University, Lawson Health Research Institute, London Health Sciences Foundation, and Academic Medical Organization of Southwestern Ontario (AMOSO) Innovation Fund. Twit Text FOAVip Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern ????JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=34081630 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34081630 #FOAvip English Wikipedia <ref>{{Cite pmid|34081630}}</ref> Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern #MMPMID34081630 Voss C; Esmail S; Liu X; Knauer MJ; Ackloo S; Kaneko T; Lowes L; Stogios P; Seitova A; Hutchinson A; Yusifov F; Skarina T; Evdokimova E; Loppnau P; Ghiabi P; Haijan T; Zhong S; Abdoh H; Hedley BD; Bhayana V; Martin CM; Slessarev M; Chin-Yee B; Fraser DD; Chin-Yee I; Li SS JCI Insight 2021[Jul]; 6 (13): ä PMID34081630show ga BACKGROUNDThe role of humoral immunity in COVID-19 is not fully understood, owing, in large part, to the complexity of antibodies produced in response to the SARS-CoV-2 infection. There is a pressing need for serology tests to assess patient-specific antibody response and predict clinical outcome.METHODSUsing SARS-CoV-2 proteome and peptide microarrays, we screened 146 COVID-19 patients' plasma samples to identify antigens and epitopes. This enabled us to develop a master epitope array and an epitope-specific agglutination assay to gauge antibody responses systematically and with high resolution.RESULTSWe identified linear epitopes from the spike (S) and nucleocapsid (N) proteins and showed that the epitopes enabled higher resolution antibody profiling than the S or N protein antigen. Specifically, we found that antibody responses to the S-811-825, S-881-895, and N-156-170 epitopes negatively or positively correlated with clinical severity or patient survival. Moreover, we found that the P681H and S235F mutations associated with the coronavirus variant of concern B.1.1.7 altered the specificity of the corresponding epitopes.CONCLUSIONEpitope-resolved antibody testing not only affords a high-resolution alternative to conventional immunoassays to delineate the complex humoral immunity to SARS-CoV-2 and differentiate between neutralizing and non-neutralizing antibodies, but it also may potentially be used to predict clinical outcome. The epitope peptides can be readily modified to detect antibodies against variants of concern in both the peptide array and latex agglutination formats.FUNDINGOntario Research Fund (ORF) COVID-19 Rapid Research Fund, Toronto COVID-19 Action Fund, Western University, Lawson Health Research Institute, London Health Sciences Foundation, and Academic Medical Organization of Southwestern Ontario (AMOSO) Innovation Fund. |Agglutination Tests/*methods[MESH] |Amino Acid Sequence[MESH] |Antibodies, Neutralizing/blood/immunology[MESH] |Antibodies, Viral/blood/immunology[MESH] |Antibody Formation/*immunology[MESH] |Antibody Specificity/immunology[MESH] |COVID-19 Serological Testing/*methods[MESH] |COVID-19/blood/*immunology/mortality[MESH] |Epitopes, B-Lymphocyte/chemistry/genetics/*immunology[MESH] |Epitopes/immunology[MESH] |Humans[MESH] |Immunity, Humoral[MESH] |Microarray Analysis/methods[MESH] |Nucleocapsid/chemistry/genetics/immunology[MESH] |Peptides/immunology[MESH] |SARS-CoV-2/genetics/*immunology[MESH] |Severity of Illness Index[MESH]Epitope-specific antibody responses differentiate COVID-19 outcomes an(epmc).pdf DeepDyve Pubget Overpricing